Boston Scientific's Promus Element Plus DES Approved in Canada

April 25, 2012—Boston Scientific Corporation (Natick, MA) announced that it has received approval from Health Canada for the Promus Element Plus everolimus-eluting platinum chromium (PtCr) coronary stent system for the treatment of coronary artery disease. The new Promus Element Plus system incorporates the Promus Element's PtCr alloy and stent design with enhanced catheter delivery. The company will begin an immediate market launch of the device in Canada.

“The unique PtCr alloy and stent architecture of the Promus Element stent offer significant advantages in conformability, radial strength, and visibility compared to other stent platforms,” commented Philippe L'Allier, MD, who performed the first patient implant of the device in Canada. “The best-in-class deliverability of the Promus Element Plus stent system will help in accessing challenging lesions.”

Cardiac Interventions Today reported in November 2011 that Boston Scientific received US Food and Drug Administration approval and launched the Promus Element Plus stent system in the United States. The company launched the device in Europe in February 2012.